To ask the Secretary of State for Health if she will take steps to ensure that rosiglitazone is freely available on the NHS to those who suffer from impaired glucose tolerance. (97303)

Rosiglitazone is licensed for the treatment of type two diabetes mellitus. It is not licensed for impaired glucose tolerance or for the prevention of diabetes.

The National Institute for Health and Clinical Excellence (NICE) published recommendations in 2003 on the use of glitazones for the treatment of type two diabetes. NICE is currently reviewing this guidance as part of a review of all of its type two diabetes guidance which is due to be published in February 2008.